These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
125 related articles for article (PubMed ID: 6528132)
1. Experience with historical control studies in cancer immunotherapy. Pinsky CM Stat Med; 1984; 3(4):325-9. PubMed ID: 6528132 [No Abstract] [Full Text] [Related]
2. Immunotherapy of malignant melanoma. Terry WD N Engl J Med; 1980 Nov; 303(20):1174-5. PubMed ID: 6999351 [No Abstract] [Full Text] [Related]
7. Controlled clinical trial of adjuvant immunotherapy with BCG and neuraminidase-treated autologous tumour cells in large bowel cancer. Gray BN; Walker C; Andrewartha L; Freeman S; Bennett RC J Surg Oncol; 1989 Jan; 40(1):34-7. PubMed ID: 2642566 [TBL] [Abstract][Full Text] [Related]
8. A randomized trial of adjuvant BCG immunotherapy in head and neck cancer. Taylor SG; Sisson GA; Bytell DE; Raynor WJ Arch Otolaryngol; 1983 Aug; 109(8):544-9. PubMed ID: 6347154 [TBL] [Abstract][Full Text] [Related]
9. Adjuvant therapy for colo-rectal cancer. Wilson RE Ann Chir Gynaecol; 1983; 72(6):290-2. PubMed ID: 6364949 [No Abstract] [Full Text] [Related]
10. [BCG-CWS as a cancer vaccine]. Hayashi A Nihon Rinsho; 2002 May; 60 Suppl 5():614-20. PubMed ID: 12101748 [No Abstract] [Full Text] [Related]
11. Antibody responses to Bacillus Calmette-Guérin during immunotherapy in bladder cancer patients. Winters WD; Lamm DL Cancer Res; 1981 Jul; 41(7):2672-6. PubMed ID: 7018669 [TBL] [Abstract][Full Text] [Related]
12. Immunotherapy of cancer patients with BCG: summary of ten years experience in Japan. Torisu M; Iwasaki K; Sakata M Dev Biol Stand; 1986; 58 ( Pt A)():451-6. PubMed ID: 3596049 [TBL] [Abstract][Full Text] [Related]
13. Adjuvant immunotherapy with bacillus Calmette-Guérin in prostatic cancer. Guinan P; Crispen R; Baumgartner G; Rao R; Totonchi E; Ablin R; John T Urology; 1979 Dec; 14(6):561-5. PubMed ID: 390811 [TBL] [Abstract][Full Text] [Related]
14. From the NIH: Only oncologists in clinical trials should use BCG vaccine for cancer treatment. JAMA; 1979 Jan; 241(1):24. PubMed ID: 758485 [No Abstract] [Full Text] [Related]
15. Randomized clinical trial of immunotherapy and androgenotherapy for remission maintenance in acute non-lymphocytic leukemia. Mandelli F; Amadori S; Dini E; Grignani F; Leoni P; Liso V; Martelli M; Neri A; Petti MC; Ferrini PR Leuk Res; 1981; 5(6):447-52. PubMed ID: 7035755 [No Abstract] [Full Text] [Related]
16. The evaluation of therapies: historical control studies. Gehan EA Stat Med; 1984; 3(4):315-24. PubMed ID: 6528131 [No Abstract] [Full Text] [Related]
17. Empiric weather report and prospectives for the future. Eilber FR Am J Clin Oncol; 1987 Feb; 10(1):2-9. PubMed ID: 3548313 [No Abstract] [Full Text] [Related]
18. Adjuvant immunotherapy or chemotherapy for malignant melanoma. Preliminary report of the National Cancer Institute randomized clinical trial. Fisher RI; Terry WD; Hodes RJ; Rosenberg SA; Makuch R; Gordon HG; Fisher SG Surg Clin North Am; 1981 Dec; 61(6):1267-77. PubMed ID: 7031934 [No Abstract] [Full Text] [Related]
19. Bacillus calmette-guerin (BCG) adjuvant therapy in stage D prostate cancer. Guinan P; Toronchi E; Shaw M; Crispin R; Sharifi R Urology; 1982 Oct; 20(4):401-3. PubMed ID: 6755855 [TBL] [Abstract][Full Text] [Related]
20. Improving the efficiency of clinical trials: a medical perspective. Moertel CG Stat Med; 1984; 3(4):455-68. PubMed ID: 6528139 [No Abstract] [Full Text] [Related] [Next] [New Search]